Techniclone (NASDAQ/TCLN) hat ein neues Krebsmittel !!!!!!!!!! Gewinne garantiert! WKN 868886 - 500 Beiträge pro Seite

[Greenspan2]

Infos unter:


News unter:
http://www.bigcharts.com/news/articles.asp?newsid=566273975&…

http://www.bigcharts.com/quickchart/quickchart.asp?symb=TCLN…


Gruß

Greenspan

vorbörslich:
http://htmlgritch.island.com/SERVICE/QUOTE?STOCK=TCLN

http://toplist.island.com/toplist/top20.jsp?SORT=6



Techniclone Announces Publication of Data on Anti-Angiogenisis Antibody
2C3


FRIDAY, SEPTEMBER 15, 2000 7:23 AM
- BusinessWire

TUSTIN, Calif., Sep 15, 2000 (BUSINESS WIRE) -- Techniclone Corporation
(NASDAQ:TCLN) announced today the publication of a paper on the activity of an
anti-angiogenisis antibody 2C3.

The paper entitled "Selective Inhibition of Vascular Endothelia Growth Factor (VEGF)
Receptor 2 (KDR/Flk-1) Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth
in Mice" was published in the September 15, 2000 issue of Cancer Research and was
co-authored by Dr. Phil Thorpe and Dr. Rolf Brekken. Both authors are consultants for
Techniclone. Dr. Thorpe is the inventor of Vascular Targeting Agent (VTA) technology which
was the focus of a recent joint venture company, ARCUS, formed by Techniclone and
OXiGENE, Inc. (NASDAQ:OXGN), as well as a licensing deal with Scotia Holdings. The
Company is also in negotiations with Supergen Corporation for the VTA technology.
Techniclone has the option to the exclusive worldwide rights to all uses of 2C3 from the
University of Texas and is currently finalizing the terms for the licensing of the antibody.

The paper demonstrates that 2C3, a monoclonal antibody against the angiogenesis factor
VEGF (Vascular Endothelial Growth Factor), selectively blocks VEGF from binding to one of
its two receptors. The authors demonstrate that the antibody blocks VEGF binding to the
receptor (KDR/Flk-1) that mediates angiogenesis (tumor blood vessel growth). Intravenous
administration of 2C3 to mice bearing various types of human solid tumors inhibits the growth
of the tumors. The unique aspect of 2C3 is that it does not block VEGF from binding to the
receptor (Flt-1) that is responsible for VEGF-induced macrophage chemotaxis and has
recently been proposed to act as a negative regulator of VEGF induced angiogenesis. This
selectivity may have beneficial clinical implications.

Dr. Bonfiglio Techniclone`s President and CEO stated, "We are excited about the publishing
of the results obtained with the 2C3 antibody. We believe that this antibody may have an
advantage over other VEGF inhibition strategies because it may be able to block the
angiogenic effects of VEGF without impairing other effects of VEGF that could cause
desirable side effects. Techniclone is pursuing a dual strategy with this exciting antibody.
We are planning to develop it as a stand-alone anti-angiogenisis inhibitor and with our joint
venture partner, OXiGENE, we are examining its use as a Vascular Targeting Agent."

Techniclone Corporation is a biopharmaceutical company focused on the development,
commercialization and licensing of unique technologies for the treatment of cancer, primarily
based on its "collateral targeting technologies." These technologies are intended to target
cell structures and cell types, rather than the surface of cancer cells, as a means to attack
solid tumors without causing damage to surrounding healthy tissue. The Company has three
collateral technologies that are currently in various stages of development: Cotara(TM),
Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA). The
Company also has a direct tumor targeting agent known as Oncolym(R) which is currently in
clinical trials for the treatment of advanced non-Hodgkins B-cell Lymphoma. Oncolym(R) has
been licensed to Schering AG, Germany, which is now responsible for all existing and future
clinical trial programs as well as marketing upon FDA approval.

Additional information on the Company and its technologies can be found at
www.techniclone.com.

Safe Harbor Statement: This release may contain certain forward-looking statements that are
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Actual events or results may differ materially from the Company`s expectations as a
result of risk factors discussed in Techniclone`s reports on file with the U.S. Securities and
Exchange Commission, including, but not limited to, the Company`s report on Form 10K for
the year ended April 30, 2000 and Form 10Q for the quarter ended January 31, 2000.

CONTACT: Techniclone Corporation, New York
Cynthia DeMonte, 800/987-8256 or 212/420-0088

URL: http://www.businesswire.com

[Greenspan2]